{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T19:53:02Z","timestamp":1761853982186,"version":"build-2065373602"},"reference-count":32,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,31]],"date-time":"2022-05-31T00:00:00Z","timestamp":1653955200000},"content-version":"vor","delay-in-days":30,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nefrolog\u00eda (English Edition)"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.nefroe.2022.05.005","type":"journal-article","created":{"date-parts":[[2022,6,7]],"date-time":"2022-06-07T09:23:28Z","timestamp":1654593808000},"page":"301-310","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Lipid profile of patients treated with evolocumab in Spanish hospital nephrology units (RETOSS NEFRO)"],"prefix":"10.1016","volume":"42","author":[{"given":"Marian","family":"Goicoechea","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vicente","family":"\u00c1lvarez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alfonso","family":"Segarra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuel","family":"Polaina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guillermo","family":"Mart\u00edn-Reyes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicol\u00e1s Roberto","family":"Robles","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ver\u00f3nica","family":"Escudero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristhian","family":"Orellana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sergio","family":"Bea Granell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joaqu\u00edn","family":"de Juan-Ribera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Milagros","family":"Fern\u00e1ndez Lucas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose Maria","family":"Gra\u00f1a","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier","family":"Reque","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosa","family":"S\u00e1nchez Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Santiago","family":"Villamayor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose Luis","family":"G\u00f3rriz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.nefroe.2022.05.005_bib0005","first-page":"78","article-title":"Prevalence of chronic renal disease in Spain: results of the EPIRCE study","volume":"30","author":"Otero","year":"2010","journal-title":"Nefrolog\u00eda"},{"key":"10.1016\/j.nefroe.2022.05.005_bib0010","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.nefro.2018.04.004","article-title":"Prevalencia de enfermedad renal cr\u00f3nica en Espa\u00f1a: impacto de la acumulaci\u00f3n de factores de riesgo cardiovascular","volume":"38","author":"Gorostidi","year":"2018","journal-title":"Nefrolog\u00eda"},{"key":"10.1016\/j.nefroe.2022.05.005_bib0015","doi-asserted-by":"crossref","first-page":"287","DOI":"10.2215\/CJN.01240215","article-title":"Predictors of Subclinical Atheromatosis Progression over 2 years in patients with different stages of CKD","volume":"11","author":"Gracia","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.nefroe.2022.05.005_bib0020","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1161\/ATVBAHA.119.312705","article-title":"Atherosclerosis in chronic kidney disease: more, less, or just different?","volume":"39","author":"Valdivielso","year":"2019","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.nefroe.2022.05.005_bib0025","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1080\/14728222.2017.1369961","article-title":"New perspectives on CKD-induced dyslipidemia","volume":"21","author":"Berm\u00fadez-L\u00f3pez","year":"2017","journal-title":"Expert Opin Ther Targets"},{"key":"10.1016\/j.nefroe.2022.05.005_bib0030","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1080\/14728222.2019.1620206","article-title":"An in-depth analysis shows a hidden atherogenic lipoprotein profile in non-diabetic chronic kidney disease patients","volume":"23","author":"Bermudez-Lopez","year":"2019","journal-title":"Expert Opin Ther Targets"},{"key":"10.1016\/j.nefroe.2022.05.005_bib0035","article-title":"Efficacy of statin treatment in early-stage chronic kidney disease","volume":"12","author":"Cho","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.nefroe.2022.05.005_bib0040","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1161\/ATVBAHA.117.309920","article-title":"Lipoprotein(a) and risk of myocardial infarction and death in chronic kidney disease: findings from the CRIC study (Chronic Renal Insufficiency Cohort)","volume":"37","author":"Bajaj","year":"2017","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.nefroe.2022.05.005_bib0045","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.atherosclerosis.2014.02.006","article-title":"Chronic kidney disease, lipids and apolipoproteins, and coronary heart disease: the ARIC study","volume":"234","author":"Lamprea-Montealegre","year":"2014","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.nefroe.2022.05.005_bib0050","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1681\/ASN.2012010037","article-title":"Sudden cardiac death: epidemiology, mechanisms, and therapeutic approaches","volume":"23","author":"Whitman","year":"2012","journal-title":"J Am Soc Nephrol JASN"},{"key":"10.1016\/j.nefroe.2022.05.005_bib0055","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1038\/ki.2011.223","article-title":"Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: Improving Global Outcomes (KDIGO)","volume":"80","author":"Herzog","year":"2011","journal-title":"Kidney Int"},{"key":"10.1016\/j.nefroe.2022.05.005_bib0060","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.arteri.2016.07.004","article-title":"Enfermedad renal cr\u00f3nica y dislipidemia","volume":"29","author":"Pascual","year":"2017","journal-title":"Cl\u00ednica E Investig En Arterioscler"},{"key":"10.1016\/j.nefroe.2022.05.005_bib0065","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1016\/S0140-6736(11)60739-3","article-title":"The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial","volume":"377","author":"Baigent","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.nefroe.2022.05.005_bib0070","doi-asserted-by":"crossref","first-page":"263","DOI":"10.7326\/0003-4819-157-4-201208210-00007","article-title":"Benefits and harms of statin therapy for persons with chronic kidney disease: a systematic review and meta-analysis","volume":"157","author":"Palmer","year":"2012","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.nefroe.2022.05.005_bib0075","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/1471-2369-12-53","article-title":"Baseline characteristics of patients with chronic kidney disease stage 3 and stage 4 in Spain: the MERENA observational cohort study","volume":"12","author":"Mart\u00ednez-Castelao","year":"2011","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.nefroe.2022.05.005_bib0080","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1056\/NEJMoa1500858","article-title":"Efficacy and safety of evolocumab in reducing lipids and cardiovascular Events","volume":"372","author":"Sabatine","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nefroe.2022.05.005_bib0085","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nefroe.2022.05.005_bib0090","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1093\/ndt\/gfz108","article-title":"Protein convertase subtilisin\/kexin type 9 biology in nephrotic syndrome: implications for use as therapy","volume":"35","author":"Busuioc","year":"2020","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nefroe.2022.05.005_bib0095","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.ekir.2020.09.046","article-title":"Efficacy and safety of PCSK9 inhibitors in hypercholesterolemia associated with refractory nephrotic syndrome","volume":"6","author":"Jatem","year":"2021","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.nefroe.2022.05.005_bib0100","first-page":"499","article-title":"Efficacy and safety of the PCSK9 inhibitors in the treatment of dyslipidemia in chronic kidney disease","volume":"40","author":"Quiroga","year":"2020","journal-title":"Nefrol Engl Ed"},{"key":"10.1016\/j.nefroe.2022.05.005_bib0105","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1002\/jca.21752","article-title":"Efficacy of Evolocumab vs low-density lipoprotein cholesterol apheresis in patients with familial hypercholesterolemia and high cardiovascular risk (EVOLAFER01)","volume":"35","author":"Torres","year":"2020","journal-title":"J Clin Apheresis"},{"key":"10.1016\/j.nefroe.2022.05.005_bib0110","unstructured":"2016 ESC\/EAS Guidelines for the Management of Dyslipidaemias | European Heart Journal | Oxford Academic (Accessed 19 April 2019). https:\/\/academic.oup.com\/eurheartj\/article\/37\/39\/2999\/2414995."},{"key":"10.1016\/j.nefroe.2022.05.005_bib0115","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.nefroe.2022.05.005_bib0120","unstructured":"Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios. Informe de Posicionamiento Terap\u00e9utico de evolocumab (Repatha\u00ae) en hipercolesterolemia. Published October, 2020 (Accessed 19 February 2021). Available on: https:\/\/www.aemps.gob.es\/medicamentosUsoHumano\/informesPublicos\/docs\/IPT-evolocumab-repatha.pdf."},{"key":"10.1016\/j.nefroe.2022.05.005_bib0125","first-page":"3N","article-title":"Rationale and management of hyperlipidemia of the nephrotic syndrome","volume":"87","author":"Grundy","year":"1989","journal-title":"Am J Med"},{"key":"10.1016\/j.nefroe.2022.05.005_bib0130","first-page":"1","article-title":"KDIGO 2012 clinical practice guideline for the evaluation and management of chronic fidney disease","volume":"3","author":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group","year":"2013","journal-title":"Kidney Int Suppl"},{"key":"10.1016\/j.nefroe.2022.05.005_bib0135","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1056\/NEJMoa0810177","article-title":"Rosuvastatin and cardiovascular events in patients undergoing hemodialysis","volume":"360","author":"Fellstr\u00f6m","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nefroe.2022.05.005_bib0140","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1056\/NEJMoa043545","article-title":"Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis","volume":"353","author":"Wanner","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nefroe.2022.05.005_bib0145","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1016\/j.jacc.2007.11.072","article-title":"Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (Treating to New Targets) study","volume":"51","author":"Shepherd","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.nefroe.2022.05.005_bib0150","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.arteri.2011.10.005","article-title":"Pitavastatina: una nueva alternativa en el tratamiento de la dislipemia","volume":"24","author":"D\u00edaz Rodr\u00edguez","year":"2012","journal-title":"Cl\u00ednica E Investig En Arterioscler"},{"key":"10.1016\/j.nefroe.2022.05.005_bib0155","first-page":"183","article-title":"Perfil cl\u00ednico de los pacientes tratados con evolocumab en unidades de l\u00edpidos\/medicina interna en Espa\u00f1a. Estudio observacional (RETOSS-IMU)","volume":"32","author":"Masana","year":"2020","journal-title":"Clin Investig Arterioscler"},{"key":"10.1016\/j.nefroe.2022.05.005_bib0160","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.recesp.2019.11.014","article-title":"Primer registro nacional de evolocumab en la pr\u00e1ctica cl\u00ednica en unidades de cardiolog\u00eda en Espa\u00f1a. Estudio RETOSS-CARDIO","volume":"73","author":"Barrios","year":"2020","journal-title":"Rev Esp Cardiol"}],"container-title":["Nefrolog\u00eda (English Edition)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2013251422000682?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2013251422000682?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T19:48:52Z","timestamp":1761853732000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2013251422000682"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":32,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["S2013251422000682"],"URL":"https:\/\/doi.org\/10.1016\/j.nefroe.2022.05.005","relation":{},"ISSN":["2013-2514"],"issn-type":[{"type":"print","value":"2013-2514"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lipid profile of patients treated with evolocumab in Spanish hospital nephrology units (RETOSS NEFRO)","name":"articletitle","label":"Article Title"},{"value":"Nefrolog\u00eda (English Edition)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nefroe.2022.05.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.nefro.2021.06.004","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier Espa\u00f1a, S.L.U. on behalf of Sociedad Espa\u00f1ola de Nefrolog\u00eda.","name":"copyright","label":"Copyright"}]}}